Adam Garsa

University of California, San Francisco

Papers

1

Total Citations

9

H-Index

1

About

Dr. Adam Garsa is a radiation oncologist whose research focuses on optimizing stereotactic body radiation therapy (SBRT) for lung cancer, particularly through advanced respiratory motion management. His major contributions center on quantifying the clinical benefits of real-time tumor tracking (RTT) compared to the internal target volume (ITV) method. In his highly cited 2018 study, Dr. Garsa demonstrated that RTT significantly reduces radiation exposure to healthy lung tissue, thereby lowering the risk of radiation pneumonitis—a critical complication in lung SBRT. This work, which has garnered 9 citations, provides essential evidence for adopting motion-adaptive techniques to improve treatment precision and patient outcomes. By systematically comparing these approaches, Dr. Garsa has helped establish RTT as a safer standard for managing respiratory motion, directly impacting clinical protocols and sparing patients from unnecessary toxicity. His research bridges technical innovation and practical oncology, offering clear guidance for clinicians seeking to minimize side effects while maintaining tumor control. Through this focused contribution, Dr. Garsa has advanced the field of lung SBRT, making treatments both more effective and better tolerated.

Research Focus

Key Achievements

1
H-Index
1
Papers
9
Total Citations
9
Avg Citations/Paper
🏆 Most Cited Paper
Influence of respiratory motion management technique on radiation pneumonitis risk with robotic stereotactic body radiation therapy
9 citations · 2018
📈 Most Prolific Year: 2018 (1 Papers)
🤝 Key Collaborators: 9
🏛 Institutions: University of California, San Francisco

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago